Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Long-Term Deferred Tax (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $4.3 million as the latest value for Q3 2024.

  • On a quarterly basis, Long-Term Deferred Tax rose 3.38% to $4.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $4.3 million, a 3.38% increase, with the full-year FY2024 number at $4.3 million, up 3.38% from a year prior.
  • Long-Term Deferred Tax was $4.3 million for Q3 2024 at Regen BioPharma, up from $4.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $4.4 million in Q3 2021 to a low of $4.1 million in Q3 2023.
  • A 3-year average of $4.3 million and a median of $4.3 million in 2024 define the central range for Long-Term Deferred Tax.
  • Biggest YoY gain for Long-Term Deferred Tax was 3.38% in 2024; the steepest drop was 3.38% in 2024.
  • Regen BioPharma's Long-Term Deferred Tax stood at $4.4 million in 2021, then dropped by 5.53% to $4.1 million in 2023, then grew by 3.38% to $4.3 million in 2024.
  • Per Business Quant, the three most recent readings for RGBP's Long-Term Deferred Tax are $4.3 million (Q3 2024), $4.1 million (Q3 2023), and $4.4 million (Q3 2021).